CONFIDENTIAL EXECUTION COPY
EXHIBIT 10.54
INSTRUMENT, ASSAY DEVELOPMENT AND LICENSE AGREEMENT
BETWEEN
WYETH-AYERST
AND
AURORA BIOSCIENCES CORPORATION
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
This Agreement is made by and between AMERICAN HOME PRODUCTS, acting through its
WYETH-AYERST LABORATORIES DIVISION ("Wyeth"), a Delaware corporation with
principal offices at X.X. Xxx 0000, Xxxxxxxxxxxx, XX 00000 and AURORA
BIOSCIENCES CORPORATION ("Aurora"), a Delaware corporation with principal
offices at 00000 Xxxxxxxxx Xxxx, Xxx Xxxxx, Xxxxxxxxxx 00000.
RECITALS
WHEREAS, Wyeth and Aurora wish to enter into an agreement involving the purcase
by Wyeth of a Voltage-Ion Probe Reader (VIPR) from Aurora, collaborative
research to develop *** assays, and licenses of rights from Aurora to Wyeth to
use the VIPR as well as Aurora's Voltage Sensor Probes (VSPs) and *** assays to
practice the technologies and the assays as set forth herein.
Now, therefore, in consideration of the foregoing and the covenants and premises
contained herein the parties agree as follows:
1. DEFINITIONS
1.1 "AURORA PATENTS" means U.S. patent *** and patent applications ***0
and *** set forth in Exhibit A and ***s and ***, *** with respect
thereto and *** patents issuing therefrom.
1.2 "AURORA TECHNOLOGY" *** the Collaborative Research Program.
1.3 "COLLABORATIVE RESEARCH PROGRAM" means the collaboration between
Aurora and Wyeth as set forth in Exhibit B for the development of ***
which may be amended from time to time, by written agreement of the
parties.
1.4 "CONFIDENTIAL INFORMATION" means all information, data, and
documentation received by either party from the other party pursuant to
this Agreement and if in writing, designated as confidential at the
time of disclosure, subject to the exceptions set forth in Section 9.1.
1.5 "CONTROL" or "CONTROLLED" means, in the context of intellectual
property, possession by a party of the ability to grant a license or
sublicense in accordance with the terms of this Agreement, and without
violating the terms of any agreement by such party with any Third
Party.
1.6 "EFFECTIVE DATE" means the latest date on which the Agreement is
executed by a party hereto.
1.7 "INVENTION" means any new and useful process, machine, manufacture,
or composition of matter, or improvement thereto, whether or not
patentable.
2/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
1.8 "KNOW-HOW" means information and data owned or Controlled by a
party hereto, which is existing as of the Effective Date or which a
party develops or acquires as part of the Collaborative Research
Program which is not generally known to the public, comprising:
designs, concepts, algorithms, formulae, techniques, practices,
processes, methods, knowledge, skill, experience, expertise and
technical information.
1.9 "MATERIALS" means any reagents, cell lines, promoters, enhancers,
vectors, plasmids, genes, proteins and fragments thereof, peptides,
antigens, antibodies, agonists, antagonists, inhibitors and chemicals.
1.10 "TRACKING RECORD" means tracking records referred to in
Section 5(e).
1.11 "PATENT RIGHTS" means all U.S. or foreign (including regional
authorities such as the European Patent Office) regular or provisional
patent applications, including any continuation, continuation-in-part,
or division thereof or any substitute application therefor or
equivalent thereof, and any patent issuing thereon, including any
reissue, reexamination or extension thereof and any confirmation patent
or registration patent or patent of additions based on any such patent,
containing one or more claims to an Invention (and in the case of an
issued patent, containing one or more claims), and for which a party
hereto owns or Controls, individually or jointly, any title thereto or
rights thereunder.
1.12 "REAGENT AGREEMENT" ***.
1.12 "TECHNOLOGY" means Materials and Know-How.
1.13 "THIRD PARTY" means any person or entity other than Aurora and
Wyeth.
1.14 "VIPR" means Aurora's voltage-ion probe reader for use with VSP's
and purchased by Wyeth ***.
1.15 "VOLTAGE SENSOR PROBES OR VSPS" means *** Aurora Patents.
1.16 "WYETH MATERIALS" means *** Collaborative Research Program.
2. EQUIPMENT PURCHASE
Aurora *** VIPR *** pursuant to this Agreement. Subject to Wyeth's payments in
Section 5, Aurora will provide the following:
- Ship *** VIPR *** or within *** of the Effective Date, ***.
3/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
- *** VIPR at Wyeth's facility ***) days of shipment, *** expense.
- Comprehensive *** VIPR for up to *** San Diego site to be scheduled
approximately one week before the ***, with *** to be ***.
- Warranty of the VIPR for *** after the Effective *** Section 5 (a).
3. COLLABORATIVE RESEARCH
Aurora will develop, in collaboration with Wyeth, ***, and *** for the *** (as
defined in the the "Collaborative Research Program"), and will *** of
representative *** and other Technology to Wyeth as described herein.
Wyeth will provide pursuant to this Agreement the following Wyeth Materials and
Confidential Information to Aurora within *** days of the Effective Date:
- *** which ***.
- *** data documenting ***.
- *** for the *** for *** into Aurora- ***, if the *** responses ***
(see Section 5.b).
- Up to ***.
- Up to *** determine *** in a *** format.
Aurora will perform pursuant to this Agreement the following:
- ***l for development of the *** incorporating *** format on the ***
within ***.
- *** development of the *** so that it can be used to *** respect ***.
4/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
- ***, if necessary, to *** for *** development.
- *** determine *** provided by Wyeth.
- *** assays ***.
- Make available *** with these assays *** for each *** for the first
year, *** to be contracted for *** Wyeth and Aurora).
The Collaborative Research Program shall be managed by a joint steering
committee of a size and composition ***, with *** from both Wyeth and Aurora,
minimally to include key representatives of Wyeth's ***. Each party shall have
*** vote in the joint steering committee. The Joint Steering Committee shall be
chaired by a *** representative. The term of the Collaborative Research Program
is *** year from the Effective Date, except for *** as provided in Section 10
below.
4. LICENSES
As of the Effective Date this Agreement, Aurora will grant to Wyeth licenses and
rights as follows:
a) A *** under the *** and *** to *** Wyeth's ***, except *** Aurora
*** b) and c) ***. Such license grant is *** the ***. The license, ***.
b) A *** under the *** to *** developed by Aurora *** Research ***.
Such license grant is ***. The license, ***.
c) A *** under the *** and *** to *** to *** developed *** or ***, and
***
5/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
research, ***, the *** is for *** only. The *** may not *** on ***. The
payments for this license are set forth in Section 5. Such license
grant is ***.
d) If the license in Section 4 (c) *** the license grant of Section 4
(c) will *** as ***. Aurora agrees that it *** including *** and/or ***
for any purpose other *** under this Agreement, and will not *** to any
Third Party without ***.
4.1 Aurora is *** and *** Wyeth that directly arise from ***.
4.2 RETAINED RIGHTS AND LIMITATIONS. The licenses under this Section 4
are subject to Wyeth's obligations described herein including payments
by Wyeth as set forth in Section 5. For clarity, the license rights
granted to Wyeth in this Section 4 specifically exclude the right ***
or ***; or 3) to *** or *** without the use of Wyeth Confidential
Information or Wyeth Materials. As consideration for the rights
received in Section 4, Wyeth *** Wyeth ***. ***.
5. PAYMENTS
a) EQUIPMENT PURCHASE. Wyeth *** Dollars ($***) for purchase ***.
Shipping will be prepaid and added FOB San Diego to the invoice. The
VIPR is provided ***, entitling Wyeth to *** of ***, prepaid and added
***. No one other than an Aurora factory certified engineer is
authorized to service the VIPR, and any tampering with or modification
of the instrument by any other party will nullify the warranty ***
cause the license *** to terminate. *** approved by Aurora, in writing,
which may include such
6/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
repairs described in training ("Authorized Maintenance"). ***.
b) COLLABORATIVE RESEARCH. Wyeth will pay Aurora a *** fee of ***
Dollars ($***) for the development of ***. This amount is payable in
*** of *** Dollars ($***) each, the *** and the *** upon *** to Wyeth.
In the event that the *** ***, as reasonably determined by Aurora,
Aurora will notify the Joint Steering Committee. If the Joint Steering
Committee agrees by *** as determined by Aurora, Aurora will notify the
Joint Steering Committee, as soon as possible and prior to the date of
*** from the Effective date. In the event, Wyeth is *** Aurora with ***
from the Effective Date, (I) *** within *** of such ***; and (ii)
Aurora shall ***. Aurora will provide reasonable telephone support for
these assays as long as the license to them is maintained.
c) LICENSE FEES. Wyeth *** license fee of *** Dollars ($***), *** on
the anniversary of the Effective Date for *** years. After the initial
***, Wyeth may extend this license, ***, *** or *** for terms to be
negotiated, in good faith, by the parties.
d) ***. Upon designation by Wyeth *** on information *** with *** or
*** above by virtue of such *** properties, Wyeth will pay Aurora ***.
On the *** for each *** will pay *** of ***. On *** for each *** will
pay *** Dollars ($***). ***. *** shall be due on *** by Wyeth as *** in
a scientifically acceptable manner *** Wyeth, even if these ***
subsequently *** VIPR or *** assays. *** the *** in either *** or
unknown *** will be due.
7/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
e) PAYMENT AND TRACKING *** shall be paid within *** days after the end
of each calendar quarter period in which *** are earned. The compounds,
screens and targets tested using a screen developed under this
Agreement will be recorded and stored by Wyeth using its customary
means and in a computer searchable database on a storage device. The
information stored *** upon in writing by the parties. Records of any
*** subject to *** or *** by Wyeth in a *** or *** that may or may not
*** related to the ***, or ***. Wyeth shall keep appropriate records of
*** assays and *** including the VSPs ***. All the records described in
this Section are collectively referred to as tracking records (the
"Tracking Records"). Wyeth will *** Aurora and agreed to by Wyeth, and
***, to *** Tracking Records *** year upon reasonable prior *** Aurora
for the *** the attainment of a milestone under this Section 5. The
Tracking Records shall be securely retained according to Wyeth's ***
than *** from *** VSPs. When a *** such as a *** or *** is *** safety
or ***, Wyeth will *** Aurora under ***. On an annual basis, *** Aurora
with a *** products that ***.
f) ***. The parties acknowledge that the principal value contributed by
Aurora under this Agreement is the ***, which the parties reasonably
believe will lessen the time required to develop new products and to
increase the efficiency of drug/target discovery and development
processes and technologies. Wyeth acknowledges and agrees that the
value it receives hereunder is in the access and use of ***;
accordingly, Wyeth *** set forth herein. Additionally, the parties
acknowledge that Aurora may not own or Control patent applications or
patents covering the manufacture, sale, use or importation of a
particular pharmaceutical product; provided, however, Wyeth ***
pharmaceutical product or compound is *** Aurora Patents.
6. OPTIONS
a) LICENSE ***. As described in Section 4 (c), the *** *** Dollars
($***) plus
8/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
milestones ***. The license ***. ***, the license *** basis or for a
*** negotiated in good faith by the parties.
b) EXTENDED WARRANTY FOR THE VIPR. Aurora will provide an extended
warranty package *** to Wyeth that includes *** and ***, prepaid and
added to the service invoice ***. The price for *** Dollars ($***)***,
increased annually by the Consumer Price Index (CPI), *** warranty
within *** of the Effective Date; ***.
c) SCIENTIFIC SUPPORT SERVICES. Aurora will provide Wyeth the
opportunity to utilize a full range of scientific support services on
licensed assays post transfer as mutually agreed in writing by the
parties. A customized program can be designed for additional long-term
support at commercially available rates beyond the scope of this
project should Wyeth desire the same.
d) TRAINING. Aurora will provide on-site training of Wyeth personnel in
the use of the VIPR. Training will be for a maximum of *** people in a
*** training program. Documentation and workbooks will be provided.
***. The price for this training program is *** Dollars ($***)***
conducted in the continental US if requested *** of the Effective Date.
7. INTELLECTUAL PROPERTY OWNERSHIP
PRE-EXISTING INTELLECTUAL PROPERTY. This agreement does not affect the ownership
of Inventions, Technology and Patent Rights of either party which existed prior
to the Effective Date.
INTELLECTUAL PROPERTY CREATED UNDER THE COLLABORATIVE RESEARCH PROGRAM. ***
developed by *** during the Collaborative Research Program will be owned by ***,
with *** as ***. ***, at its sole discretion, shall be responsible for the
filing and prosecution of all applicable patents and the expenses thereof. ***.
INTELLECTUAL PROPERTY ***. Any Inventions, Technology and Patent Rights relating
to the activities or properties of *** or other ***, *** of the licenses granted
by Aurora under Section 4. *** will be responsible for the filing and
prosecution of all applicable patents and for the expenses thereof. Any
improvements, Know-How, Inventions, Technology and Patent Rights
9/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
developed *** VIPR or VSPs or their use will *** to Sections ***. ***.
TRANSFER OF RIGHTS. All rights not expressly licensed or assigned by Aurora are
retained by Aurora and no implied licenses are conveyed herein or were conveyed
before the Effective Date. Except as otherwise expressly provided in this
Agreement, nothing in this Agreement is intended to convey or transfer ownership
by one party to the other of any rights, title or interest in any Confidential
Information, Technology, copyrights or Patent Rights owned or Controlled by a
party. Except as expressly provided for in this Agreement, nothing in this
Agreement shall be construed as a license or sublicense by one party to the
other of any rights in any Technology, copyrights, or Patent Rights owned or
Controlled by a party.
INVENTORSHIP AND ASSIGNMENT. Inventorship of patentable inventions shall be
determined by U.S. patent law. Wyeth and Aurora ***.
COPYRIGHTS. The parties agree to treat and handle, to the maximum extent
practical, any copyrights owned or Controlled by a party in the same manner as
Patent Rights owned or Controlled by such party.
8. PRODUCT DEVELOPMENT, COMMERCIALIZATION AND DILIGENCE
Wyeth will *** and such development and commercialization ***.
*** the Effective Date, and will *** Wyeth within ***of the Effective Date. The
*** will be made available to Wyeth in accordance with the *** between *** as
indicated in Section 3.
9. CONFIDENTIALITY
9.1 CONFIDENTIAL INFORMATION. Except as expressly provided herein, the
parties agree that, for the term of this Agreement and five (5) years
thereafter, the receiving party shall keep completely confidential and
shall not publish or otherwise disclose to another party and shall not use
for any purpose other than to perform the purposes contemplated by this
Agreement any Confidential Information furnished to it by the disclosing
party hereto pursuant to this Agreement, except that to the extent that it
can be established by the receiving party by competent proof that such
Confidential Information:
was already known to the receiving party, other than under an
obligation of confidentiality, at the time of disclosure;
10/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
was generally available to the public or otherwise part of the
public domain at the time of its disclosure to the receiving
party;
became generally available to the public or otherwise part
of the public domain after its disclosure and other than
through any act or omission of the receiving party in breach
of this Agreement;
was lawfully disclosed to the receiving party by a person
other than a party hereto,
or was independently developed by the receiving party
without the use of Confidential Information.
9.2. PERMITTED USE AND DISCLOSURES. Each party hereto may use or disclose
Confidential Information disclosed to it by the other party to the extent
such use or disclosure is (i) reasonably necessary in filing or prosecuting
patent applications, prosecuting or defending litigation, (ii) complying
with applicable law, governmental regulation or court order, (iii)
submitting information to tax or other governmental authorities, (iv)
making a permitted sublicense or (v) otherwise exercising its rights
hereunder, provided that if a party is required to make any such disclosure
of another party's Confidential Information, other than pursuant to
subsection (ii) hereof, it will give reasonable advance notice to the
latter party of such disclosure and, shall obtain the prior written
approval of said latter party, which approval shall not be unreasonably
withheld.
9.3 CONFIDENTIAL TERMS. Except as expressly provided herein, each party
agrees not to disclose any material or financial terms of this Agreement to
another party without the consent of the other party, not to be
unreasonably withheld; provided, however, each party reserves the right to
make reasonable disclosures (including the redaction of material or
financial terms) as required by securities or other applicable laws, or to
actual or prospective investors or corporate partners (including licensees
and acquirers), or to accountants, attorneys and other professional
advisors on a need-to-know basis under circumstances that reasonably ensure
the confidentiality thereof, or to the extent required by law. If such
Confidential Information is to become public information by such disclosure
the disclosing party must obtain the written consent of the non-disclosing
party in order to obtain protection of the Confidential Information if
necessary.
9.4 PRESS RELEASE. Notwithstanding the foregoing, the parties agree that
Aurora will make a press release to announce the execution of this
Agreement which shall be subject to prior written approval of Wyeth, such
approval not to be unreasonably withheld. Thereafter, Wyeth and Aurora may
each disclose to Third Parties the information contained in the mutually
agreed upon press release without the need for further approval by the
other.
10. TERM AND TERMINATION OF THE RESEARCH COLLABORATION
a) TERM. The Collaborative Research Program will terminate *** Wyeth,
or after ***, unless extended by mutual written agreement of both
parties through the Joint
11/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
Steering Committee. If the Collaborative Research Program *** Wyeth's
***, Wyeth will *** payment of *** Dollars ($***) described in Section
*** above. In this case, the license described under Section *** and
*** would *** Wyeth would *** for *** and to *** these assays under the
terms of *** and pursuant to this Agreement, with *** or *** to Aurora,
*** the VSPs, in which case it *** described in Section *** and ***.
b) TERMINATION. Either party shall have the right to terminate this
Agreement at any time during the term for a material breach of this
Agreement by the other party, provided that the non-breaching party
shall have first given *** days prior written notice (*** days in the
event of non-payment of any amounts due under this Agreement) to the
breaching party describing such breach and stating the non-breaching
party's intention to terminate this Agreement if such breach remains
uncured, and the breaching party thereafter fails to cure same within
such *** day (***) period (*** day period in the event of non-payment
of any amounts due under this Agreement).
c) EFFECT OF EXPIRATION OR TERMINATION. Except as otherwise expressly
provided in this Agreement, the rights and obligations of the parties
hereof shall terminate and be of no further force or effect whatsoever
upon any termination of this Agreement under Section 10 hereof.
Sections *** shall survive termination or expiration of this Agreement.
Upon expiration or other termination of the Agreement all licenses
granted will thereby terminate and Materials will be destroyed or
returned at the direction of the parties within *** days.
11. MISCELLANEOUS
11.1.BINDING EFFECT; ASSIGNMENT. This Agreement shall be binding upon the
parties' permitted successors and permitted assigns. Wyeth may not assign
or otherwise transfer this Agreement or any of its rights or obligations
hereunder without the prior written consent of Aurora *** such attempted
assignment or transfer shall be void. Aurora may assign or otherwise
transfer this Agreement without the consent of Wyeth.
11.2. EFFECT OF WAIVER. No waiver of any default, condition, provisions or
breach of this Agreement shall be deemed to imply or constitute a waiver of
any other like default, condition, provision or breach of this Agreement.
11.3. REPRESENTATIONS AND WARRANTIES OF AURORA AND WYETH. Each Party hereby
represents and warrants: Such party is duly organized and validly existing
and in good standing under the laws of the state of its incorporation and
has all requisite corporate power and authority to enter into this
Agreement and to carry out the provisions hereof. Such party is duly
authorized to execute and deliver this Agreement and to perform its
obligations hereunder. This Agreement is a legal and valid obligation
binding upon it and enforceable in accordance
12/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
with its terms. The execution, delivery and performance of this Agreement
by such party does not conflict with any agreement, instrument or
understanding, oral or written, to which it is a party or by which it may
be bound, nor violate any law or regulation of any court, governmental body
or administrative or other agency having jurisdiction over it.
11.3.1 Aurora hereby represents and warrants to Wyeth that, to the best
of its knowledge:
(a) ***
(b) as of the Effective Date, it has the full right, power and
authority to grant the licenses granted to Wyeth hereunder;
(c) ***;
(d) it is the exclusive licensee of the Aurora Patents and Aurora
Technology existing as of the Effective Date, ***.
(e) ***
11.4. ***
11.4.1. ***
11.4.2. ***
13/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
11.4.3. ***
11.5. FORCE MAJEURE. Neither party shall lose any rights hereunder or be
liable to the other party for damages or losses (except for payment
obligations) on account of failure of performance by the defaulting party
if the failure is occasioned by war, strike, fire, act of God(s),
earthquake, flood (including El Nino and La Nina), lockout, embargo and
governmental acts or orders or restrictions.
11.6. AMENDMENT. No modification, supplement to or waiver of this Agreement
or any Addendum hereto or any of their provisions shall be binding upon a
party hereto unless made in writing and duly signed by an authorized
representative of both Wyeth and Aurora. In no event may the terms of this
Agreement be changed, deleted, supplemented or waived by any notice,
purchase order, receipt, acceptance, xxxx of lading or other similar form
of document. A failure of either party to exercise any right or remedy
hereunder, in whole or in part, or on one or more occasions, shall not be
deemed either a waiver of such right or remedy to the extent not exercised,
or of any other right or remedy, on such occasion, or a waiver of any right
or remedy on any succeeding occasion.
11.7. ENTIRE AGREEMENT. This Agreement and each supplemental written
agreement contemplated hereunder, sets forth the entire understanding and
agreement of the parties as to the subject matter thereof, and there are no
other understandings, representations or promises, written or verbal, not
set forth herein or on which either party has relied. If any provisions of
any such Addendum or supplemental written agreement conflict with any
provisions set forth in this Agreement, the provisions of this Agreement
shall take precedence, unless such Addendum or supplemental written
agreement expressly refers to the specific provision(s) of this Agreement
that it is intended to replace or modify (and which shall be limited in
force and effect to such Addendum or supplemental written agreement only).
11.8. NOTICES. All Notices under this Agreement shall be given in writing
and shall be addressed to the parties at the following addresses:
FOR WYETH:
Wyeth-Ayerst Laboratories
X.X. Xxx 0000
Xxxxxxxxxxxx, XX 00000
Attn: SVP, Global Business Development
14/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
Copy to: American Home Products Corporation
0 Xxxxxxx Xxxxx
Xxxxxxx, XX 00000
Attn: SVP and General Counsel
FOR AURORA:
Xxxxxxx X. Xxxx, M.D., X.Xx.
CEO and Chairman
Aurora Biosciences Corporation
00000 Xxxxxxxxx Xxxx
Xxx Xxxxx, XX. 00000
COPIES TO:
Xxxx X. Xxxxxxxx, Ph.D., X.X.
Senior Vice President, Intellectual Property
and Chief Knowledge Officer
Aurora Biosciences Corporation
00000 Xxxxxxxxx Xxxx
Xxx Xxxxx, XX. 00000
Notices shall be in writing and shall be deemed delivered when received, if
delivered by a courier, or on the second business day following mailing, if
sent by first-class certified or registered mail, postage prepaid.
11.9. RESOLUTION. The parties recognize that disputes as to certain matters
may from time to time arise during the term of this Agreement which relate
to either party's rights and/or obligations hereunder. It is the objective
of the parties to establish procedures to facilitate the resolution of
disputes arising under this Agreement in an expedient manner by mutual
cooperation and without resort to resolution by other means. The parties
agree that prior to any resolution concerning this Agreement, *** will meet
in person or by video-conferencing in a good faith effort to resolve any
disputes concerning this Agreement. Within *** days of a formal request by
either party to the other, any party may, by written notice to the other,
have such dispute referred to their respective officers designated or their
successors, for attempted resolution by good faith negotiations, such good
faith negotiations to begin within *** after such notice is ***.
11.10. GOVERNING LAW. This Agreement shall be governed by and construed in
accordance with the laws ***, without regard or giving effect to its
principles of conflict of laws.
11.11. THIRD PARTY BENEFICIARIES. This Agreement and the rights and
obligations created hereunder are for the sole benefit of the parties
hereto and their respective successors or assigns as may be permitted under
the terms of this Agreement. By entering into this Agreement, the parties
agree that they are not creating and do not intend to create implied or
incidental rights inuring to the benefit of Third Parties.
15/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
11.12. SEVERABILITY. This Agreement is intended to be severable. If any
provision(s) of this Agreement are or become invalid, are ruled illegal by
a court of competent jurisdiction or are deemed unenforceable under the
current applicable law from time to time in effect during the term hereof,
it is the intention of the parties that the remainder of the Agreement
shall not be affected thereby and shall continue to be construed to the
maximum extent permitted by law at such time. It is further the intention
of the parties that in lieu of each such provision which is invalid,
illegal, or unenforceable, there shall be substituted or added as part of
this Agreement by such court of competent jurisdiction a provision which
shall be as similar as possible, in economic and business objectives as
intended by the parties to such invalid, illegal or unenforceable
provision, but shall be valid, legal and enforceable.
11.13. HEADINGS. Captions and paragraph headings are for convenience only
and shall not form an interpretative part of this Agreement. Unless
otherwise specifically provided, all references to a Section incorporate
all Sections or subsections thereunder. This Agreement shall not be
strictly construed against either party hereto and maybe executed in two
(2) or more counterparts, each of which will be deemed an original and the
same instrument. Counterparts may be signed and delivered by facsimile,
each of which shall be binding when sent, and in each case an original
shall be sent via overnight courier. This Agreement will not be enforceable
and shall have no effect if this Agreement is not executed by Wyeth and
Aurora ***.
IN WITNESS WHEREOF, the parties have executed, by duly authorized
representatives, this Agreement:
By: /s/ Xxxx X. Xxxx By: /s/ Xxxxxxx X. Xxxx
---------------------------- ------------------------------
Date: 12/16/99 Date: November 18, 1999
-------------------------- ----------------------------
Name: Xxxx X. Xxxx Name: Xxxxxxx X. Xxxx
--------------------------- ----------------------------
Title: Vice President Title: V.P. Business Development
-------------------------- ---------------------------
For American Home Products For Aurora Biosciences Corporation
Acting through its Wyeth-Ayerst
Laboratories Division
16/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
EXHIBIT A
AURORA PATENTS
***
17/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
EXHIBIT B
DESCRIPTION OF COLLABORATIVE RESEARCH PROGRAM
[GRAPHIC]
***
18/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
***
19/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
***
20/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
***
21/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
EXHIBIT C
***
22/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
***
23/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
EXHIBIT 1.1
***
24/25
*** CONFIDENTIAL TREATMENT REQUESTED
CONFIDENTIAL EXECUTION COPY
EXHIBIT 1.2
***
25/25
*** CONFIDENTIAL TREATMENT REQUESTED
